Advances in the diagnosis and treatment of growth hormone insensitivity disorders have
occurred in the past 15 years. We discuss the current status of endocrine and molecular …

The potential therapeutic applications of the insulin-like growth factors (IGFs) are broad. This
review focuses on treatment of humans with recombinant human IGF-I (rhIGF-I), and with a …

Context: GH insensitivity syndrome (GHIS), Laron syndrome, is characterized by severe
short stature, high serum GH levels, and very low serum IGF-I and IGF-binding protein-3 …

Mecasermin rinfabate, a complex of equimolar amounts of insulin-like growth factor (IGF)-I
and its binding protein IGFBP-3, has been approved by the US Food and Drug …

Growth hormone insensitivity (GHI) describes a broad range of clinical disorders
characterized by insensitivity to the biologic actions of GH. This article focuses on three …

Growth hormone-insensitivity syndrome (GHIS) is usually caused by mutations in the growth
hormone receptor. Recombinant IGF-I has been used to treat GHIS either alone …

Insmed is developing mecasermin rinfabate, a recombinant complex of insulin-like growth
factor-I (rhIGF-I) and binding protein-3 (rhIGFBP-3)[insulin-like growth factor-I/insulin-like …

Somatomedin-1 binding protein-3 has potential as replacement therapy for somatomedin-1
which may become depleted in indications such as major surgery, organ damage/failure …